Oncolytics names Gill as SVP, regulatory affairs
2002-10-10 05:19 PT - News Release
Dr. Brad Thompson reports
ONCOLYTICS BIOTECH ANNOUNCES APPOINTMENT OF SENIOR VICE PRESI ...
Oncolytics Biotech has appointed Dr. George M. Gill, MD, as senior vice-president, clinical and regulatory affairs.
"Dr. Gill has more than 30 years of senior-level experience in clinical research and regulatory affairs, and has established an outstanding track record, having supported the advancement of more than 20 products -- including 11 cancer products -- through the regulatory approval process in the United States, Canada and Europe," said Dr. Brad Thompson, president and chief executive officer of Oncolytics. "As part of our senior management team, Dr. Gill will play a pivotal role in advancing our proprietary product, Reolysin, through clinical and regulatory processes."
Dr. Gill has been a consultant to the industry since 1999, when he retired from Ligand Pharmaceuticals, where he was vice-president of clinical research and later, medical affairs. Prior to that, he was the senior director and head of United States clinical and medical affairs for ICI Pharmaceuticals (now AstraZeneca). Before that, he was vice-president and head of worldwide regulatory affairs for the Bristol-Myers Company (now Bristol-Myers Squibb). Dr. Gill began his career in the industry at Hoffman-La Roche where he held several clinical and regulatory positions, ending as director of the clinical oncology group. Dr. Gill holds a BSc (chemistry) from Dickinson College in Pennsylvania and an MD from the school of medicine at the University of Pennsylvania. He is board certified in pediatrics. Dr. Gill has acted as an independent consultant to Oncolytics for the past year, providing counsel on negotiation of the regulatory process in Canada and the U.S.
"After a year of consulting with Oncolytics," said Dr. Gill, "I look forward to advancing the studies of Reolysin, which is an intriguing agent with significant potential as a cancer therapeutic. I am excited about this opportunity." |
